Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mayne Banks On Nextstellis As Generics Business Suffers

Company Sees 6% Decline In Revenues But Dermatology Portfolio Continues To Grow

Executive Summary

Mayne Pharma has expressed confidence after its recent US launch of Nextstellis (estetrol/drospirenone) 14.2mg/3mg oral contraceptive tablets. While the firm’s overall sales dipped by 6% in its financial first half, Mayne expects its recent and near-term launches, particularly key dermatology products, to help reverse the trend.

You may also be interested in...



Mayne Pharma Pursues ‘Aggressive Rationalization’ To Rally Revenue

Mayne’s 2022 results take stock of pivotal changes, with the Australian firm drawing down its generics portfolio as it focuses on the US branded products market. These new priorities come amid a high-value asset sale and a change in CEO.

Mayne And Mithra Obtain Long-Awaited NuvaRing Nod From FDA

Following a trio of complete response letters received since late 2018, Mayne Pharma and partner Mithra Pharmaceuticals have finally obtained US FDA approval for a generic version of Organon’s NuvaRing vaginal hormonal contraceptive ring.

Three Not A Magic Number For Mayne With Another NuvaRing CRL

Australia’s Mayne Pharma has announced another complete response letter for its proposed generic version of Organon’s NuvaRing (etonogestrel/ethinylestradiol) contraceptive device, marking a trio of setbacks for the ANDA product.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151707

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel